Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study
about
Temozolomide for children and adolescents with diffuse intrinsic pontine gliomaNew chemotherapy strategies and biological agents in the treatment of childhood ependymomaMolecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and TreatmentSystemic analysis of gene expression profiles identifies ErbB3 as a potential drug target in pediatric alveolar rhabdomyosarcomaComparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases.Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.Differences in molecular genetics between pediatric and adult malignant astrocytomas: age matters.Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumorsThe use and effectiveness of temozolomide in children with central nervous system tumours: a survey from the Canadian Paediatric Brain Tumour ConsortiumPreclinical testing of erlotinib in a transgenic alveolar rhabdomyosarcoma mouse model.Growth-factor-driven rescue to receptor tyrosine kinase (RTK) inhibitors through Akt and Erk phosphorylation in pediatric low grade astrocytoma and ependymomaExogenous HGF Bypasses the Effects of ErbB Inhibition on Tumor Cell Viability in Medulloblastoma Cell LinesEGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance.Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investmentImproving the outcome for children with cancer: Development of targeted new agents.Molecular profiling of childhood cancer: Biomarkers and novel therapiesLong-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology.Advances in paediatric cancer treatmentTemozolomide and/or Erlotinib in the Treatment of Lung Cancer Patients With Progressive Central Nervous System Metastases.Neurotoxicity of biologically targeted agents in pediatric cancer trialsBiologically targeted therapeutics in pediatric brain tumors.Cell survival signaling in neuroblastoma.The rationale for targeted therapies in medulloblastoma.Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy.Nimotuzumab in pediatric glioma.A review of erlotinib--an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor.Phase II Trial of Erlotinib during and after Radiotherapy in Children with Newly Diagnosed High-Grade Gliomas.Molecular sub-group-specific immunophenotypic changes are associated with outcome in recurrent posterior fossa ependymomaTargeted therapy for soft tissue sarcomas in adolescents and young adults.Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma.Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.New targets and targeted drugs for the treatment of cancer: an outlook to pediatric oncology.Emerging drugs for neuroblastoma.Chemotherapy for osteosarcoma - where does it come from? What is it? Where is it going?ErbB receptors as prognostic and therapeutic drug targets in bone and soft tissue sarcomas.EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma.Advances in emerging drugs for the treatment of neuroblastoma.Unified approach for extrapolation and bridging of adult information in early-phase dose-finding paediatric studies.A Novel EGFR Extracellular Domain Mutant, EGFRΔ768, Possesses Distinct Biological and Biochemical Properties in NeuroblastomaA feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG).
P2860
Q24200164-88E95E64-DFB6-47F4-A2DF-4B2BD70D781CQ24658324-2B8B19F9-E641-4C19-BCC8-2D18E0F6C0F3Q26785952-C9278B53-E545-4922-997E-E051E306E24BQ28485467-3CB6B0C8-893A-48C3-9531-951EC15C02EAQ33574627-5A7B3B9F-F012-437C-975E-4518DB382216Q34193975-2EA287DB-E813-4C4C-8180-97FE5A774D28Q34286305-2203C581-C7CF-4FF5-ABE2-340B2AC97BCCQ34480582-CD5C0DE1-47A3-4F18-AE9B-70BD8960A9AAQ34541456-79B3EA2B-0F1B-4B88-8ABA-0D9E215CE133Q34929504-DDEDB2F3-AF4F-401F-B3AB-7C937719AC70Q35583984-41D6E046-62E1-4E57-A876-E719C26F85FCQ35818728-D3CBA753-3FE7-43FC-BA36-2E381014D1C9Q35829712-2E1CF174-646B-4B54-8259-E983A43DB3F4Q35958048-29E3B9F1-61D8-4B2A-BF4E-312B3B8DFD18Q36238795-6DE4245F-0C5A-4816-8BC3-C0A336B16A3EQ36250783-2C1E36AB-5DC9-47A3-B6E4-D2949DF98C8BQ36261364-D143B6D2-565A-47B7-BF5F-FCD8DFE5506BQ36508630-2B3B9089-A8E9-47FB-A567-903B86A06934Q36682422-5CD1C69A-02B7-4D4E-BB7A-D3A63FF0ABBAQ36766221-752A42A4-F32A-44E4-BA79-45DD4C9EB6D9Q36844744-C1D88E86-C294-476B-BDD2-91487FD3FF65Q37010166-28F0CC7B-DB2D-468E-B6AC-B6FDEE6720EFQ37409736-77D3ED08-798A-40C5-9A98-F447065FB7AFQ37564201-C10E8996-BFB0-4687-ADB9-15CFCBC16FD4Q37630569-1810E30C-4D7D-4913-9857-F563BFC53946Q37678436-D33A83B6-B1FE-4F29-A4C7-4612288B168BQ37689492-79F140BD-1586-4E40-BF2F-64CB3B773CB2Q37705192-6A21FFFC-746D-4B41-AEFF-65D401DDA64BQ37742014-5F1279EB-1E2C-41EB-8A16-15A257E1EFDBQ37831148-E76737E0-7E1E-4720-A939-46D6B204B439Q37873453-2D0F8045-B837-44C3-8DFC-3468B27451B5Q37936432-7645759B-89FB-4F56-9CE9-2BA74AFC1E90Q38108399-E1827611-589B-4AA5-8E7B-82E011AFDEE7Q38126943-ED2F18CF-70AA-481F-89B3-88F6FCC3AD59Q38263000-E1BB9944-41F5-4F12-9F86-E3467C467FB1Q38901662-4777246A-9DFB-4639-ADBE-C68CD5639159Q39158415-639CED54-8FA0-4E0C-896A-9A43F2DA2701Q39321056-A58C0ECD-3932-425E-A953-F2D6E99870F8Q41738897-88E3CEA9-D2CE-4E82-A77A-A89EB2890461Q46088442-907050CB-C158-4A80-BF9B-61789F31FC87
P2860
Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pediatric phase I and pharmaco ...... Group Phase I Consortium Study
@en
Pediatric phase I and pharmaco ...... roup Phase I Consortium Study.
@nl
type
label
Pediatric phase I and pharmaco ...... Group Phase I Consortium Study
@en
Pediatric phase I and pharmaco ...... roup Phase I Consortium Study.
@nl
prefLabel
Pediatric phase I and pharmaco ...... Group Phase I Consortium Study
@en
Pediatric phase I and pharmaco ...... roup Phase I Consortium Study.
@nl
P2093
P2860
P356
P1476
Pediatric phase I and pharmaco ...... Group Phase I Consortium Study
@en
P2093
Ashish M Ingle
Janet E Dancey
Jean Tersak
Mark D Krailo
Marta Hamilton
Peter C Adamson
Regina I Jakacki
Richard J Gilbertson
Stephan D Voss
P2860
P304
P356
10.1200/JCO.2007.15.2306
P407
P577
2008-09-15T00:00:00Z